Rate My Professor Gertrude Yap

Yap's research focuses on pharmacokinetics and xenobiotic interactions with drug metabolizing enzymes such as CYP2E1, development of early biomarkers for diabetic nephropathy, translational studies of diabetic nephropathy, teaching and learning methods in medical education, and early biomolecules associated with metabolic syndromes, obesity, and pre-diabetes. Her technical expertise encompasses HPLC, LC-MS/MS, genomics using Genespring and Partek software, proteomics, metabolomics, bioinformatics, animal experimental models, and cell culture. Notable publications include "Strategies for optimization of hypoglycemia rat models" (2025), "In Silico exploration of Karanjin for anti-obesity potential through ADMET profiling, network pharmacology, molecular docking, and molecular dynamics simulations" (2025), "Influence of Clinical Risk Factors on International Normalized Ratio Control in Patients on Warfarin Therapy: A Systematic Review" (2025), "Environmental enrichment and the combined interventions of EE and metformin enhance hippocampal neuron survival and hippocampal-dependent memory in type 2 diabetic rats under stress through the BDNF-TrkB signaling pathways" (2024), and "Targeted CYP2E1 quantification and its correlation to currently acceptable clinical biochemical indices" (2016). She has garnered awards such as Best Presentation at the 5th World Congress on Diabetes and Metabolism (2014, Las Vegas), Best Presentation at the 2nd World Congress on Clinical Trials in Diabetes (2017, Berlin), and First Prize at Monash CSJB Research Week (2017). Recent funding includes a Seed Grant Award (2024). Ongoing projects investigate renal protection by tocotrienol-rich vitamin E in type 2 diabetes rat models (2024–2027), anti-obesity effects of Karanjin (2023–2026), and neuroprotective effects of environmental enrichment in diabetic rats.